(以下内容从国金证券《医药行业行业研究:慢阻肺专题深度:慢病蓝海疗法迭代,国产新药BD潜力凸显》研报附件原文摘录)投资逻辑慢阻肺疾病负担沉重,亟待更优治疗方案。慢阻肺是以慢性呼吸道症状(呼吸困难、咳嗽、咳痰)和持续性气流阻塞为主要特征的常见病,我国患者人数约1亿,已成为最常见慢性疾病之一。慢阻肺也是我国2021年第3大死亡原因,疾病危害性强,其中急性加重是加速疾病进展导致早期死亡的关键环节。现阶段...
Source Link(以下内容从国金证券《医药行业行业研究:慢阻肺专题深度:慢病蓝海疗法迭代,国产新药BD潜力凸显》研报附件原文摘录)投资逻辑慢阻肺疾病负担沉重,亟待更优治疗方案。慢阻肺是以慢性呼吸道症状(呼吸困难、咳嗽、咳痰)和持续性气流阻塞为主要特征的常见病,我国患者人数约1亿,已成为最常见慢性疾病之一。慢阻肺也是我国2021年第3大死亡原因,疾病危害性强,其中急性加重是加速疾病进展导致早期死亡的关键环节。现阶段...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.